Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Strong Light for Sore Eyes

Today’s primary glaucoma treatment involves application of eye drops-as often as ten times a day-to reduce pressure in the eye caused by blocked drainage canals. But a new company called Solx, based at Boston University’s Photonics Center, is developing a high-energy laser that can reduce and even eliminate reliance on daily medications for the estimated three million people with glaucoma in the United States. Solx’s infrared laser emits quick pulses of light, producing acoustic shock waves in the eye that physically shake and unclog the drainage canals. “It’s like beating a carpet with a tennis racket,” says president and CEO Doug Adams. The lasers now used to treat some glaucoma patients emit powerful continuous beams that, as a side effect, burn tissue in the eye. Because this leaves permanent scars, patients can only undergo this procedure once or twice. The Solx treatment leaves no scars and can be performed annually. The company plans to seek regulatory approval of the treatment this spring and expects to launch the product by the end of the summer.


0 comments about this story. Start the discussion »

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me